Editas Medicine
EDIT
75 hedge funds and large institutions have $300M invested in Editas Medicine in 2016 Q3 according to their latest regulatory filings, with 24 funds opening new positions, 23 increasing their positions, 15 reducing their positions, and 15 closing their positions.
60% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 15
53% more repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 15
10% more funds holding
Funds holding: 68 → 75 (+7)
0% more funds holding in top 10
Funds holding in top 10: 5 → 5 (0)
45% less capital invested
Capital invested by funds: $550M → $300M (-$250M)
63% less call options, than puts
Call options by funds: $44K | Put options by funds: $120K
Top Buyers
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$14.7M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$9.43M |
| 3 |
SM
Sabby Management
Miami Beach,
Florida
|
+$2.77M |
| 4 |
Renaissance Technologies
New York
|
+$2.17M |
| 5 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
+$2.15M |
Top Sellers
| 1 |
PVMCV
Polaris Venture Management Co VI
Boston,
Massachusetts
|
-$10.2M |
| 2 |
AI
Alphabet Inc
Mountain View,
California
|
-$6.26M |
| 3 |
Jennison Associates
New York
|
-$4.13M |
| 4 |
EC
EcoR1 Capital
San Francisco,
California
|
-$2.08M |
| 5 |
Morgan Stanley
New York
|
-$945K |
EDIT Hedge Fund Activity: Q3 2016 in Review
75 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Editas Medicine (EDIT) for Q3 2016, worth a combined $300M — down 45% from $550M a quarter earlier.
Buyers outnumbered sellers: 24 funds opened new EDIT positions and 15 closed out — a net gain of 9 holders — while 23 added to existing stakes and 15 trimmed.
The largest buyer was Vanguard Group, adding an estimated $14.7M. The largest seller was Polaris Venture Management Co VI, cutting an estimated $10.2M.
- 75 institutional investors held Editas Medicine (EDIT) as of Q3 2016, up from 68 in Q2 2016.
- Funds reported $300M of Editas Medicine stock for Q3 2016, down 45% quarter-over-quarter.
- 24 funds opened new Editas Medicine positions in Q3 2016 and 15 closed out, a net change of +9 holders.
- The largest Editas Medicine buyer in Q3 2016 was Vanguard Group, an estimated $14.7M added.
- The largest Editas Medicine seller in Q3 2016 was Polaris Venture Management Co VI, an estimated $10.2M sold.
Based on aggregated 13F filings for Q3 2016.